favipiravir

02/01/2021 - "Significant improvement in time to clinical cure suggests favipiravir may be beneficial in mild-to-moderate COVID-19."
01/01/2021 - "Treatment with favipiravir has shown promising improvement in the clinical status of COVID-19 patients, although the results suggested no significant differences in some clinical parameters such as length of hospitalizations and clinical recovery. "
11/30/2022 - "Further research is needed to ascertain if higher favipiravir doses are effective and safe for patients with COVID-19. "
01/01/2021 - "Favipiravir was superior to the SOC in shortening the time to clinical improvement in patients with mild to moderate COVID-19."
02/01/2023 - "Favipiravir can be effective for clinical and laboratory improvement of COVID-19 patients, and it is a promising drug for decreasing of mortality rate in these patients."

10/12/2015 - "Favipiravir remained highly effective against lethal LASV infection when treatments were initiated nine days post-infection, a time when animals were demonstrating advanced signs of disease. "
01/01/2018 - "Effective Treatment of Experimental Lymphocytic Choriomeningitis Virus Infection: Consideration of Favipiravir for Use With Infected Organ Transplant Recipients."
02/27/2022 - "Provided that further in vivo experiments confirm its efficacy, favipiravir would be useful for the treatment of severe HAV infection."
01/01/2023 - "The findings in this study demonstrate the utility of SCID mouse for in vivo drug efficacy evaluation and the potential efficacy of favipiravir against CHPV infection."
01/01/2021 - "All clinical trials which addressed the safety and efficacy of Favipiravir in comparison to other control groups for treatment of patients with confirmed infection with SARS-CoV2 were included. "

11/20/2018 - "Moreover, 5 h was more effective against the clinical isolate A/California/7/2009 (H1N1pdm) strain than the influenza viral polymerase inhibitor, favipiravir (T-705). "
01/01/2022 - "Favipiravir has been developed as an anti-influenza agent, and this agent may be effective against these viruses in vitro. "
01/01/2017 - "Favipiravir is effective against a wide range of types and subtypes of influenza viruses, including strains resistant to existing anti-influenza drugs. "
09/22/2023 - "Serial plasma samples were collected from adults with uncomplicated influenza who were randomized to favipiravir (1800 mg BID on day 1, 800 mg BID on days 2 to 5)(N = 827) or placebo (N = 419) in two phase 3 trials. "
12/01/2022 - "We also mention trials of favipiravir and lumicitabine, for influenza and respiratory syncytial virus, respectively. "

01/01/2022 - "Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia."
06/01/2021 - "Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia."
12/01/2021 - "Our results showed that Favipiravir and Hydroxycholoroquine shorten viral clearance and clinical recovery time and promote pneumonia absorption. "
01/01/2021 - "The aim of this descriptive article is to share the experience in Ege University, Turkey with favipiravir in the treatment of severe SARS-CoV-2 pneumonia. "
01/01/2021 - "Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey"

01/01/2018 - "Erratum for Madelain et al., "Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses"."
01/01/2017 - "Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses."
07/01/2021 - "From the third day of favipiravir treatment; the patient did not have a fever and her complaints regressed. "
07/01/2021 - "The days from the onset of fever to defervescence showed a positive correlation with the duration from the onset of fever to initiation of favipiravir treatment (r = 0.548, P < 0.001). "
05/01/2021 - "A decrease in the serum concentration of favipiravir was observed along with resolution of the fever. "